title: Nasopharygeal carcinoma in Queensland, Australia: a review of 10 years experience.
abstract: The purpose of this study was to compare the treatment outcomes of patients with nasopharyngeal carcinoma in Queensland in a 10-year period during which synchronous chemoradiotherapy has come into use and to compare characteristics of patients of different racial origins and their prognostic factors. Eighty-one patients treated between 1991 and 2001 at the Queensland Radium Institute, Brisbane, Queensland for histologically confirmed nasopharyngeal carcinoma were included. Seventeen patients were treated using the Intergroup protocol, 32 patients with miscellaneous synchronized chemoradiotherapy, 6 patients with neoadjuvant regimens and 26 patients with radiotherapy only. Asian patients were found to present earlier than White Australian patients (P < 0.02). No significant difference was identified in the histological presentation between the two ethnic groups. Asian patients were more likely to have a relapse and poor loco-regional control. Overall survival, however, was not different. Patients treated according to the Intergroup protocol had better disease-specific survival and relapse-free survival than the other groups. The median follow up was 36 months. Twenty-five patients (30%) developed recurrent disease. The 5-year salvage survival or survival after relapse was 15%. Our experience with the Intergroup protocol in our population is similar to other studies, with likelihood of improved results.
authors.affiliation: Oncology Department, Royal Brisbane and Women's Hospital, Herston Road, Brisbane, Queensland, Australia. clement_wong1@excite.com
authors.forename: C H-K
authors.initials: CH
authors.lastname: Wong
authors.forename: L E
authors.initials: LE
authors.lastname: Kelly
authors.forename: L B
authors.initials: LB
authors.lastname: Tripcony
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D044466:Asian People / Q000706:statistics & numerical data; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D011379:Prognosis; D016016:Proportional Hazards Models; D011793:Queensland / Q000453:epidemiology; D016879:Salvage Therapy / Q000379:methods / Q000706:statistics & numerical data; D012737:Sex Factors; D016019:Survival Analysis; D016896:Treatment Outcome; D044465:White People / Q000706:statistics & numerical data